id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2000-E-0238-0003,FDA,FDA-2000-E-0238,Certificate Extending Patent Term from U.S. Patent and Trademark Office,Rule,Certificate Extending Patent Term,2006-09-15T04:00:00Z,2006,9,,,2025-06-30T23:01:23Z,,0,0,09000064804d59b0
FDA-2000-E-0238-0002,FDA,FDA-2000-E-0238,Letter from Associate Director for Policy Center for Drug Evaluation and Research to  U.S. Patent and Trademark Office,Other,Letter(s),2003-11-21T05:00:00Z,2003,11,,,2025-06-30T23:00:01Z,,0,0,09000064804d59af
FDA-2000-E-0238-0001,FDA,FDA-2000-E-0238,Determination of Regulatory Review Period for Purposes of Patent Extension; Rapamune,Notice,General Notice,2003-02-19T05:00:00Z,2003,2,2003-02-19T05:00:00Z,2003-04-15T03:59:59Z,2025-06-30T21:25:25Z,,0,0,09000064804d598f